Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Kymera Therapeutics reported new preclinical data demonstrating that KT-579, an oral IRF5 degrader, showed potent disease-modifying activity in inflammatory bowel disease models, performing comparably or better than current therapies. The ongoing Phase 1 trial in healthy volunteers is expected to yield data in the second half of 2026, supporting th…